Annovis Bio Inc
ANVS
AMX
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
11.00
USD
-0.03
(-0.27%)
Optionable: No Market Cap: 88 M 90-day average vol: 77,618
Previous close: 11.03 Open: 11.1 Bid: 12.5 Ask: 12.5
52 week range
8.39 43.37
Last updated: Friday 5th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 2.20 |
PE Ratio (TTM) | -5.20 |
Book Value per Share ($) | 5.15 |
5 Year PE Range | -9.2 , -8.7 |
Returns
7 Day Return | -3.93% | |
1 Month Return | -11.15% | |
3 Month Return | 4.66% | |
1 Year Return | -69.99% | |
3 Year Return | 14.70% | |
5 Year Return | 14.70% | |
YTD Return | -37.43% |
Risk
Financial Health
Technicals
RSI (14 Day) | 40.66 |
14 Day SMA ($) | 11.87 |
14 Day EMA ($) | 11.71 |
Money Flow Index | 37.20 |
Average True Range | 0.98 |
50 Day SMA ($) | 11.57 |
200 Day SMA ($) | 15.94 |
ADX | 12.32 |
MACD | -0.28 |
Growth
Free Cash Flow QoQ Growth | 70.79% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -4.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Yahoo Finance 3/3/2022
Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City
Yahoo Finance 1/28/2022
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
Yahoo Finance 1/25/2022
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Yahoo Finance 1/25/2022
As Annovis Bio, Inc.'s market cap (NYSE:ANVS) drops to US$117m, insiders might be questioning their decision to buy earlier this year
Yahoo Finance 1/19/2022
Annovis Bio (ANVS) Investor Presentation - Slideshow
Seeking Alpha 1/11/2022
Annovis Bio Enhances Leadership Team with Two Senior Appointments
Yahoo Finance 1/10/2022
Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M
Yahoo Finance 1/7/2022
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Yahoo Finance 1/5/2022
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Yahoo Finance 1/3/2022
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Yahoo Finance 12/20/2021
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
Yahoo Finance 12/14/2021
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Yahoo Finance 11/20/2021
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
Yahoo Finance 11/15/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Financials
ANVS Income Statement
Annual
| Invalid date | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | |
| Cost of sales | 0 | 0 | 0 | 0 | 0 | |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 409063 | 602329 | 94291 | 2 M | 6 M | |
| Research & development expense | 273370 | 111608 | 776256 | 3 M | 8 M | |
| Operating income | -682433 | -713937 | -870547 | -5 M | -15 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | |
| Other income net | 0 | 0 | -79500 | -26500 | 0 | |
| Pre-tax Income (EBT) | -682349 | -713871 | -990980 | -5 M | -14 M | |
| Income taxes | 0 | 0 | 0 | 0 | 0 | |
| Net income from total operations | -682349 | -713871 | -990980 | -5 M | -14 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -682349 | -713871 | -990980 | -5 M | -14 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -682349 | -713871 | -990980 | -5 M | -14 M | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | |
| Amortization | 0 | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -682433 | -713937 | -870547 | -5 M | -15 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.16 | -0.16 | -0.17 | -0.87 | -1.9 | |
| Diluted EPS total | -0.16 | -0.16 | -0.17 | -0.87 | -1.9 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!